Clinical Trial Update: The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating whether a COX-2 inhibitor can increase radiosensitivity in nasopharyngeal carcinoma; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• COX-2 inhibitor (COX-2 inhibitor)

Snippet

Sponsor: Changjie Huang | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: UNKNOWN